COST-EFFECTIVENESS OF TOFACITINIB IN ACTIVE PSORIATIC ARTHRITIS AFTER CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS TREATMENT IN SPAIN

被引：0
|
作者：
Vazquez, M. [1 ]
Canete, J. D. [2 ]
Nicolas, J. [3 ]
Peral, C. [4 ]
Gomez, S. [4 ]
Lopez, A. [4 ]
Prades, M. [5 ]
Rebollo, F. [4 ]
机构：
[1] Hosp Ramon & Cajal, Rheumatol Dept, Madrid, Spain
[2] Hosp Clin Barcelona, Rheumatol Dept, Barcelona, Spain
[3] Hosital Univ Mutua Terrassa, Pharm Dept, Terrassa, Spain
[4] Pfizer SLU, Madrid, Spain
[5] Outcomes10, Castellon De La Plana, Spain
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSY16
引用
收藏
页码：S904 / S904
页数：1
相关论文
共 50 条
  • [41] Psoriatic Disease: Update on Traditional Disease-modifying Antirheumatic Drugs
    Marchesoni, Antonio
    Lubrano, Ennio
    Cauli, Alberto
    Ricci, Massimo
    Manara, Maria
    JOURNAL OF RHEUMATOLOGY, 2015, 42 : 61 - 64
  • [42] A pooled analysis of the safety of tofacitinib as monotherapy or in combination with background conventional synthetic disease-modifying antirheumatic drugs in a Phase 3 rheumatoid arthritis population
    Kivitz, Alan J.
    Cohen, Stanley
    Keystone, Edward
    van Vollenhoven, Ronald F.
    Haraoui, Boulos
    Kaine, Jeffrey
    Fan, Haiyun
    Connell, Carol A.
    Bananis, Eustratios
    Takiya, Liza
    Fleischmann, Roy
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2018, 48 (03) : 406 - 415
  • [43] Conventional Synthetic Disease-modifying Antirheumatic Drugs (DMARDs) for the Treatment of Non-infectious Uveitis
    Tappeiner, Christoph
    Rath, Thomas
    Heiligenhaus, Arnd
    KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE, 2018, 235 (05) : 562 - 567
  • [44] Cost effectiveness of adding leflunomide to a 5-year strategy of conventional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis
    Maetzel, A
    Strand, V
    Tugwell, P
    Wells, G
    Bombardier, C
    ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2002, 47 (06): : 655 - 661
  • [45] Oral Conventional Synthetic Disease-Modifying Antirheumatic Drugs with Antineoplastic Potential: a Review
    Cho-Hsun Hsieh
    Yi-Wei Huang
    Tsen-Fang Tsai
    Dermatology and Therapy, 2022, 12 : 835 - 860
  • [46] Cost-effectiveness of biologic compared with conventional synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a Register study
    Joensuu, Jaana T.
    Aaltonen, Kalle J.
    Aronen, Pasi
    Sokka, Tuulikki
    Puolakka, Kari
    Tuompo, Riitta
    Korpela, Markku
    Vasala, Mikko
    Ilva, Kirsti
    Nordstrom, Dan
    Blom, Marja
    RHEUMATOLOGY, 2016, 55 (10) : 1803 - 1811
  • [47] Oral Conventional Synthetic Disease-Modifying Antirheumatic Drugs with Antineoplastic Potential: a Review
    Hsieh, Cho-Hsun
    Huang, Yi-Wei
    Tsai, Tsen-Fang
    DERMATOLOGY AND THERAPY, 2022, 12 (04) : 835 - 860
  • [48] PREDICTING LIVER TOXICITY CAUSED BY CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS
    Kuusalo, L.
    Venalainen, M.
    Saranpaa, S.
    Kirjala, H.
    Elo, L.
    Pirila, L.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 517 - 518
  • [49] Update on the use of conventional disease-modifying antirheumatic drugs in the management of rheumatoid arthritis
    Feely, Michael G.
    O'Dell, James R.
    CURRENT OPINION IN RHEUMATOLOGY, 2010, 22 (03) : 316 - 320
  • [50] Combination of methotrexate with oral disease-modifying antirheumatic drugs in psoriatic arthritis: a systematic review
    Hsieh, Tyng-Shiuan
    Tsai, Tsen-Fang
    IMMUNOTHERAPY, 2024, 16 (02) : 115 - 130
12345